Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511823 · ClinicalTrials.gov registry record · Phase 1
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00511823 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT00511823, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adults
Interventions
- DRUG rosiglitazone
- DRUG casopitant
- DRUG granisetron
- DRUG dolasetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-07-23 |
| Est. Completion | 2007-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511823
The ClinicalTrials.gov registry entry for NCT00511823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rosiglitazone is the first listed.
NCT00511823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511823 about?
NCT00511823 is a clinical study titled "The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects". This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adults
What is the current status of trial NCT00511823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-07-23. Estimated completion is 2007-09-21.
What interventions are being tested in trial NCT00511823?
The interventions under investigation include: rosiglitazone (DRUG), casopitant (DRUG), granisetron (DRUG), dolasetron (DRUG).
Who is sponsoring clinical trial NCT00511823?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.